Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies

Journal of Virology

Volumn 76, Issue 5, 2002, Pages 2123-2130

  Nishimura, Yoshiaki ^a   Igarashi, Tatsuhiko ^a   Haigwood, Nancy ^a   Sadjadpour, Reza ^a   Plishka, Ron J ^a   Buckler White, Alicia ^a   Shibata, Riri ^a   Martin, Malcolm A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; IMMUNOGLOBULIN G; RNA; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELL SUSPENSION; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; INFECTION PREVENTION; INOCULATION; LYMPH NODE CELL; MACACA; NONHUMAN; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; STATISTICAL ANALYSIS; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ANIMALS; DNA, VIRAL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MACACA NEMESTRINA; NEUTRALIZATION TESTS; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0036170921     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.76.5.2123-2130.2002     Document Type: Article

References (36)

1. 8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
2. T lymphocyte responses in HIV-1 infection: Implications for vaccine development
3. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
4. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma
5. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection
6. Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus
7. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
8. Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus
9. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
10. Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody
11. Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile
12. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis 4. Final report of results based on clinical diagnoses
13. Infection of HTLV-III/LAV in HTLV-carrying cells MT-2 and MT-4 and application in a plaque assay
14. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs
15. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
16. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
17. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
18. Mechanisms of human immunodeficiency virus type 1 (HIV-1) neutralization: Irreversible inactivation of infectivity by anti-HIV-1 antibody
19. T cell responses and viral escape
20. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
21. Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes
22. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site
23. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
24. A simple method of estimating fifty percent endpoints
25. Effects of rapid mass immunization of a population with live oral poliovirus vaccine under conditions of massive enteric infection with other viruses
26. Persistence of immunity following administration of formalin-treated poliovirus vaccine
27. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
28. Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo
29. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
30. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing
31. Reactivation of HIV type 1 in chronically infected chimpanzees following xenostimulation with human cells or with pulses of corticosteroid
32. Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures
33. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity